Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin versus vancomycin or teicoplanin for complicated skin and soft tissue infections
2005-001349-40Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in skin and soft tissue infections (SSTIs) comparing Daptomycin with vancomycin or teicoplanin (2 arms). Primary endpoint: Clinical success at test-of-cure. Started Jun 2005; status: terminated.
02
Drugs
daptomycinvancomycinteicoplanin
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2005-001349-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001349-40.